Opendata, web and dolomites

PROGSY SIGNED

Prosaposin and GPR37 in synucleinopathies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PROGSY project word cloud

Explore the words cloud of the PROGSY project. It provides you a very rough idea of what is the project "PROGSY" about.

dopaminergic    underlying    linked    co    normal    intracellular    fragment    incl    membraneous    dimer    technological    parkinson    hallmark    consistently    single    released    disease    bodies    prosaposin    neurotoxic    structures    insights    progression    pathogenic    synuclein    receptor    enzyme    gpcrs    gene    gba    survival    stress    secreted    diagnosis    accumulation    aggregation    hypothesize    suggest    pet    regulates    psap    anti    membrane    neurotrophic    treatment    versus    fluorescence    propensity    agonists    prosaptide    synucleinopathies    spectroscopy    neuroprotective    aggregated    neurons    located    initiate    tracers    label    cellular    alpha    parkin    correlation    pd    dopamine    exceptional    atomic    injury    saposin    autopsy    relative    multimerization    cgpr37ko    constituent    lewy    advancements    agonism    mice    protein    acute    gpcr    contributions    grossly    trafficking    modeling    lrrk2    molecule    neurotoxicity    examine    prosaptides    transduced    lysosomal    interference    function    plasma    gpr37    dj    virally    delineate    lbs    unexpectedly    neuroprotection    breakthrough    ligands    mechanistic    cue    pathological    drug    pivotal   

Project "PROGSY" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 1˙950˙033 €
 EC max contribution 1˙950˙033 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-CoG
 Funding Scheme ERC-COG
 Starting year 2015
 Duration (year-month-day) from 2015-08-01   to  2020-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 1˙950˙033.00

Map

 Project objective

The next breakthrough in the treatment of synucleinopathies, incl Parkinson´s disease (PD), will be aimed at interference of disease progression based on insights into the underlying pathogenic process. The pathological hallmark of PD are Lewy bodies (LBs), in which α-synuclein is the major constituent together with other PD-linked gene products (DJ-1, LRRK2, parkin, and GBA) and aggregated GPR37. GPR37 is exceptional among GPCRs having a high propensity for intracellular receptor accumulation and aggregation leading to neurotoxicity. However, unexpectedly, our results suggest that GPR37 is neuroprotective in dopaminergic when located at the plasma membrane. Consistently, prosaposin (PSAP), and its neurotrophic fragment prosaptide, were recently identified as agonists at GPR37. PSAP is a neuroprotective protein that regulates intracellular lysosomal enzyme function, with saposin C being a co-factor of GBA. In addition, we hypothesize that PSAP is secreted following cellular stress and, via membraneous GPR37, cue dopamine neurons to initiate survival pathways. Pivotal to this programme is modeling and analysis of the atomic structures of GPR37 in complex with prosaptide, which will grossly facilitate mechanistic understanding and drug development with potential use in diagnosis and treatment. Novel applications and technological advancements of fluorescence correlation spectroscopy will be implemented for single molecule trafficking of GPR37 and its ligands and will examine whether GPCR multimerization beyond dimer formation may be neurotoxic. Normal and cGPR37KO mice will be virally transduced by α-synuclein to delineate in the relative contributions of improved lysosomal function versus GPR37 agonism for neuroprotection by prosaptides. Evolving from the autopsy studies that anti–GPR37 label LBs and that prosaposin is released upon cellular injury, we will develop GPR37 ligands as PET tracers for LBs in synucleinopathies.

 Publications

year authors and title journal last update
List of publications.
2020 Zhang X, Mantas I, Fridjonsdottir E, Andrén PE, Chergui K and Svenningsson P
Deficits in motor performance, neurotransmitters and synaptic plasticity in elderly and experimental parkinsonian mice lacking GPR37
published pages: 84-89, ISSN: 1663-4365, DOI: 10.3389/fnagi
Frontiers in Aging Neuroscience 2020.00084 2020-04-01
2017 Cyril Monnot, Xiaoqun Zhang, Sahar Nikkhou-Aski, Peter Damberg, Per Svenningsson
Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism
published pages: 11-20, ISSN: 0014-4886, DOI: 10.1016/j.expneurol.2017.02.014
Experimental Neurology 292 2019-06-07
2017 Leinartaité Lina, Svenningsson Per
Folding Underlies Bidirectional Role of GPR37/Pael-R in Parkinson Disease.
published pages: , ISSN: 0165-6147, DOI:
Trends in Pharmacological Sciences 2019-06-07

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROGSY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROGSY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

EXTREME (2020)

The Epistemology and Ethics of Fundamentalism

Read More  

THERMONANO (2018)

Nanoassemblies for the subcutaneous self-administration of anticancer drugs

Read More  

iNANOVAC4CANCER (2019)

BIOHYBRID AND BIODEGRADABLE NANOVACCINES FOR CANCER IMMUNOTHERAPY

Read More